Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07354919 · ClinicalTrials.gov registry record · Phase 2
Axelopran for Advanced Cancer in Patients Receiving Opioids
A Phase 2 study, sponsored by HealthPartners Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT07354919 is a Phase 2 study that is actively recruiting participants, run by HealthPartners Institute. The registered enrollment target is 34 participants.
The verdict
NCT07354919, a Phase 2 study, is actively recruiting participants, sponsored by HealthPartners Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 weeks). The main questions it aims to answer are: * Does axelopran show a signal for efficacy in slowing tumor progression? * Is axelopran safe and tolerable for long-term use in this patient population? * Does axelopran show a signal for efficacy in improving bowel function and quality of life? * Does axelopran show a signal for efficacy in reducing systemic inflammation, cachexia, and prognostic serum biomarkers of inflammation? Patients will take axelopran as monotherapy after relapse or progression on or after standard systemic therapy. Clinician and patient must be willing to attempt a delay in next line of systemic cancer therapy (if available) until day 43 to assess change in cancer status on repeat imaging. Clinician can move to the next line of therapy whenever deemed clinically necessary. Participants will: * take oral axelopran capsules daily for up to 1 year, or longer if deriving benefit * attend 10 in-person study visits, each lasting approximately 1-2 hours * complete study procedures including but not limited to imaging exams, blood draws, electronic health surveys, and physical assessments
Interventions
- DRUG axelopran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07354919
The ClinicalTrials.gov registry entry for NCT07354919 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which axelopran is the first listed.
NCT07354919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07354919 about?
NCT07354919 is a clinical study titled "Axelopran for Advanced Cancer in Patients Receiving Opioids". The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 weeks). The main que...
What is the current status of trial NCT07354919?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2026-04-27. Estimated completion is 2028-11-01.
What interventions are being tested in trial NCT07354919?
The interventions under investigation include: axelopran (DRUG).
Who is sponsoring clinical trial NCT07354919?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.